Tak 901

Manufactured by Selleck Chemicals

TAK-901 is a laboratory chemical product offered by Selleck Chemicals. It is a molecular compound used for various research and scientific applications. The core function of TAK-901 is to serve as a research tool in experimental settings, without any interpretation or extrapolation on its intended use.

Automatically generated - may contain errors

Lab products found in correlation

4 protocols using tak 901

Combination Inhibition of Triple-Negative Breast Cancer

Check if the same lab product or an alternative is used in the 5 most similar protocols

MDA-MB-231, MDA-MB-361, and MDA-MB-436 were screened against 1000 nM of AZD1152-HQPA and GSK-1070916, 100 nM of TAK-901, in combination with 16 nM of ZAK siRNA. TAK-901 and GSK-1070916 were purchased from Selleck (S2718, S2740) while AZD1152-HQPA was purchased from ChemieTek (CT-A1152H).
Percentage inhibition values in the CellTiter-Glo assay and percentage cytotoxicity values in the CellTox Green assay were calculated by using DMSO as negative control and 100 µM benzethonium chloride (BzCl) as positive control. The HSA synergy score was calculated.

Tang J., Gautam P., Gupta A., He L., Timonen S., Akimov Y., Wang W., Szwajda A., Jaiswal A., Turei D., Yadav B., Kankainen M., Saarela J., Saez-Rodriguez J., Wennerberg K, & Aittokallio T. (2019). Network pharmacology modeling identifies synergistic Aurora B and ZAK interaction in triple-negative breast cancer. NPJ Systems Biology and Applications, 5, 20.

+ Open protocol

+ Expand

Kinase and Cancer Compound Preparation

Check if the same lab product or an alternative is used in the 5 most similar protocols

Gefitinib (cat# 13166) was purchased from Cayman Chemical. Afatinib (cat# S1011), AZD9291 (osimertinib, cat# S7297), BGB324 (R428, cat# S2841), TAK-901 (cat# S2718), as well as the kinase inhibitor (cat# L1200) and anti-cancer (cat# L3000) compound libraries were all purchased from Selleckchem. All drug stock solutions were prepared in dimethylsulfoxide (DMSO) and stored at −20 °C. Gefitinib used for in vivo studies were clinical grade tablets for human dosage while TAK-901 (cat# HY-12201) used for in vivo studies was purchased from MedChemExpress.

Low J.L., Lau D.P., Zhang X., Kwang X.L., Rohatgi N., Chan J.V., Chong F.T., Wong S.Q., Leong H.S., Thangavelu M.T., Rikka S., Skanderup A.M., Tan D.S., Periyasamy G., Koh J.L., Iyer N.G, & DasGupta R. (2021). A chemical genetic screen identifies Aurora kinases as a therapeutic target in EGFR T790M negative, gefitinib-resistant head and neck squamous cell carcinoma (HNSCC). EBioMedicine, 64, 103220.

+ Open protocol

+ Expand

SCLC Cell Line Characterization

Check if the same lab product or an alternative is used in the 5 most similar protocols

All SCLC cell lines were provided by Dr. John V. Heymach (MD Anderson Cancer Center, Houston, TX) and Dr. Gerold Bepler (Barbara Ann Karmanos Cancer Institute, Detroit, MI). All cell lines, maintained in a central bank at Moffitt, were authenticated by STR analysis (ACTG Inc, Wheeling, IL), and all are routinely tested and shown to be negative for mycoplasma (PlasmoTest, InvivoGen, San Diego, CA). All cell lines were grown in RPMI 1640 media with 10% fetal bovine serum (GIBCO, Grand Island, NY) and maintained at 37°C in a humidified incubator with 5% CO₂ atmosphere. The Roche Kinase Inhibitor Set was a gift of Hoffman-La Roche (San Diego, CA). SNS-314, danusertib, AT9283, MLN-8237, ENMD-2076, TAK-901, AZD1152, and VX-680 were purchased from Selleckchem (Houston, TX). The TANK-binding kinase 1 (TBK1) inhibitor Compound II and BX-795 were provided by Dr. Michael White (University of Texas Southwestern Medical Center, Dallas, TX).

Li J., Fang B., Kinose F., Bai Y., Kim J.Y., Chen A., Rix U., Koomen J.M, & Haura E.B. (2016). Target identification in small cell lung cancer via integrated phenotypic screening and activity-based protein profiling. Molecular cancer therapeutics, 15(2), 334-342.

+ Open protocol

+ Expand

Screening Library of FDA-Approved Drugs

Check if the same lab product or an alternative is used in the 5 most similar protocols

The screening library (1154 FDA-approved drugs) as well as ENMD-2076 (S1181) and TAK-901 (S2718) were purchased from Selleck. Other chemicals were supplied by Shanghai Institute of Materia Medica. All chemicals were dissolved in DMSO for the in vitro studies.

Wang H., Li S., Wang Q., Jin Z., Shao W., Gao Y., Li L., Lin K., Zhu L., Wang H., Liao X, & Wang D. (2021). Tumor immunological phenotype signature-based high-throughput screening for the discovery of combination immunotherapy compounds. Science Advances, 7(4), eabd7851.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!